Company intelligence / Profile preview

MindAd

New York, New York, United Statesmindadmedia.com ↗

Ownership: Private
Development stage: Other

Overview

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates—primarily psychedelic-inspired small molecules—to treat brain health disorders. Its lead asset, MM120 ODT, has advanced to Phase 3 trials in generalized anxiety disorder. The company also has ongoing development of MM120 ODT for major depressive disorder and additional preclinical or early clinical assets targeting psychiatric conditions. In December 2024, MindMed joined the Nasdaq Biotechnology Index after raising $250 million to support its expanded pipeline.

Therapeutic areas: Psychiatry
Modalities: Small moleculePsychedelic-based therapy
Industry: Biotech

Beyond the preview

Go deeper on MindAd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MindAd.

Explore the full profile